Tirzepatide dose schedule (Mounjaro & Zepbound)

Verified May 10, 2026: Tirzepatide is the second drug in the dual-agonist family. It activates both the GLP-1 receptor and the GIP receptor. The clinical effect is steeper weight loss (~21% of body weight in SURMOUNT-1, NEJM 2022 vs ~15% for semaglutide). The titration tradeoff is a longer ramp with more side effects per step.

The 6-step ladder

Mounjaro and Zepbound use the same ladder. Both move every 4 weeks. Both can be held or backed off:

That's six steps over a minimum of 24 weeks if you advance every 4 weeks without a hold. Most users hold at least once. Source: Mounjaro FDA label.

Why dual-agonist ramps move slower

Two reasons:

• Higher peak side effects. Tirzepatide's nausea, diarrhea, and GI motility shifts are more pronounced step-for-step than semaglutide's. The clinical trials saw all-cause discontinuation rise from ~1.4% at 2.5 mg to ~7% at 5 mg. Most people who quit do so on the climb.
• GIP-receptor adaptation takes longer. The GLP-1 component activates appetite suppression in week 1. The GIP component takes 2-3 weeks to show effects on insulin sensitivity. Holding each step for the full 4 weeks gives the GIP arm time to catch up.

The dose people actually stay on

In long-term data, the median sustainable dose is 7.5 mg or 10 mg weekly. The 12.5 mg and 15 mg doses exist for users who plateau on the lower ones.

Tachyphylaxis (the drug "wearing off") is rare on tirzepatide compared to semaglutide. The number on the scale is the only signal you need: if weight is still moving on 5 mg, do not advance.

Compounded tirzepatide and the same ramp

The ramp from the FDA label applies to compounded versions identically. What differs is concentration variability. See the full compounded tirzepatide guide.

• Concentrations vary vial-to-vial more than semaglutide. A 30 mg vial in 1 mL gives 30 mg/mL. The same vial in 2 mL gives 15 mg/mL. Three different syringe-unit answers for the same prescription.
• Vial volume math compounds errors. Tirzepatide doses are smaller (2.5 mg = ~10 units on a U-100 syringe at 25 mg/mL). A 1-unit drawing error at 12.5 mg is a 2% deviation; at 2.5 mg it's a 10% deviation.
• Stability windows are shorter. Compounded tirzepatide carries a 28-day BUD post-reconstitution. Aged solution above 4 weeks loses potency quickly.

How Titrate handles the dual-agonist data

The plasma-decay chart in Titrate is built per-compound, and tirzepatide's curve looks different from semaglutide's. Half-life is ~5 days vs semaglutide's ~7. The next-dose timer reads from actual pharmacokinetics, not a hardcoded weekly reminder.

Multi-compound stacking matters here. The cohort of users titrating tirzepatide while running BPC-157, ipamorelin, or a research peptide for adjunct effect is large enough that single-compound apps don't serve them.

Frequently asked questions

Why does tirzepatide ramp slower than semaglutide?

Two reasons: higher peak side effects per step (nausea, diarrhea), and the GIP receptor component takes 2-3 weeks longer to adapt than the GLP-1 component alone. The 4-week hold lets both receptor classes plateau before the next bump.

Should I push to 15 mg if I want maximum weight loss?

Not unless your current dose has plateaued. Most long-term users settle at 7.5 mg or 10 mg. Higher doses produce diminishing returns and steeper side-effect profiles.

Can I switch from semaglutide to tirzepatide?

Yes, but you restart the titration ladder at 2.5 mg. The two drugs are not interchangeable at equivalent doses; tirzepatide's GIP component changes the side-effect profile.

Is Mounjaro the same as Zepbound?

Same molecule, same manufacturer (Eli Lilly), different FDA approvals. Mounjaro is approved for type 2 diabetes; Zepbound for chronic weight management. The titration ladder is identical.